Teva Pharmaceutical Industries Limited logo

Teva Pharmaceutical Industries Limited

TEVA US

Teva Pharmaceutical Industries LimitedUnited States Composite

17.00

USD
-0.12
(-0.70%)
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.
Business
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Company News

  • U.S. drug shortages worsen to reach a decade high: report

  • Teva accuses Corcept of monopolizing the market for Korlym

  • AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate

  • If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today

  • Teva asthma inhaler patents are 'improperly listed' in FDA Orange Book

  • Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

  • TEVA Stock Rises 135% in a Year: What's Driving the Recovery?

  • New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)

  • Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024

  • Teva wins FDA nod for new Austedo formulation

  • Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24--48 mg/day)

  • Teva Pharmaceutical Indus's Options Frenzy: What You Need to Know

  • GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals

  • Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla

  • Teva, Alvotech launch biosimilar against AbbVie’s Humira

  • Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

  • Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

  • Insider Sale: Chief Accounting Officer Amir Weiss Sells 28,135 Shares of Teva Pharmaceutical ...

  • Insider Sale: Chief Accounting Officer Amir Weiss Sells 28,135 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

  • Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations